Abeona Therapeutics Receives Orphan Drug Designation in the European Union for EB-101

Abeona Therapeutics receives Orphan Drug Designation by the European Medicines Agency for its gene therapy clinical trial for patients with recessive dystrophic epidermolysis bullosa.

Read More  >